Loading clinical trials...
Loading clinical trials...
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients With Episodic Migraine
The main purpose of this study is to evaluate whether the study drug known as galcanezumab is safe and effective in the prevention of migraine headaches.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Clinical Research Advantage
Gilbert, Arizona, United States
21st Century Neurology
Phoenix, Arizona, United States
Arizona Research Center
Phoenix, Arizona, United States
Pharmacology Research Institute, Long Beach
Encino, California, United States
Collaborative Neuroscience Network - CNS
Long Beach, California, United States
Pharmacology Research Institute, Long Beach
Los Alamitos, California, United States
Pharmacology Research Institute, Long Beach
Newport Beach, California, United States
Desert Valley Research
Rancho Mirage, California, United States
Artemis Institute for Clinical Research
San Diego, California, United States
Medical Center for Clinical Research
San Diego, California, United States
Start Date
July 7, 2014
Primary Completion Date
August 19, 2015
Completion Date
February 12, 2018
Last Updated
November 23, 2018
414
ACTUAL participants
Galcanezumab
DRUG
Placebo
DRUG
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions